Face to Face Treatment for Parenting

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Parenting+4 More
Promoting Engagement with ADHD Pre-Kindergarteners - Behavioral
Eligibility
< 18
All Sexes
What conditions do you have?
Select

Study Summary

This trial is examining the efficacy of two forms of delivery of behavior parent education (face-to-face and online) for reducing symptoms of ADHD in children aged 3-5, relative to a wait-list control condition. The objective is to see if the results from a previous smaller trial can be replicated with a larger and more diverse sample, and to assess the cost and cost-effectiveness of the two delivery formats.

Eligible Conditions
  • Parenting
  • Attention Deficit Hyperactivity Disorder (ADHD)
  • Relation, Parent-Child
  • Children Behavior

Treatment Effectiveness

Study Objectives

30 Primary · 0 Secondary · Reporting Duration: 5 years

10 weeks
Post-Treatment Effects (Child): Academics
Post-Treatment Effects (Child): Bedtime Behaviors
Post-Treatment Effects (Child): Behavior
Post-Treatment Effects (Child): Behavior Observations
Post-Treatment Effects (Child): Self Regulation
Post-Treatment Effects (Parent): Acceptability
Post-Treatment Effects (Parent): Behavior
Post-Treatment Effects (Parent): Intervention Strategies
Post-Treatment Effects (Parent): Optimism
Post-Treatment Effects (Parent): Stress
2 years
Maintenance (Child): Bedtime Behaviors
Maintenance (Child): Behavior Observations
Maintenance (Child): Self Regulation
Maintenance (Parent): Acceptability
Maintenance (Parent): Behavior
Maintenance (Parent): Intervention Strategies
Maintenance (Parent): Optimism
Maintenance (Parent): Stress
Mediators and Moderators (Child)
Mediators and Moderators (Parent): ADHD Symptoms
Mediators and Moderators (Parent): Demographics
Mediators and Moderators (Parent): Media
Mediators and Moderators (Parent): Parent Strategies
Mediators and Moderators (Parent): Session Completion
Mediators and Moderators (Parent): Stress
Post-Treatment Effects (Child): Social Behaviors
5 years
Cost-Effectiveness (money): Face-to-face
Cost-Effectiveness (money): Online
Cost-Effectiveness (time): Face-to-face
Cost-Effectiveness (time): Online

Trial Safety

Trial Design

2 Treatment Groups

Face to Face Treatment
1 of 2
Online Treatment
1 of 2
Experimental Treatment

180 Total Participants · 2 Treatment Groups

Primary Treatment: Face to Face Treatment · No Placebo Group · N/A

Face to Face Treatment
Behavioral
Experimental Group · 1 Intervention: Promoting Engagement with ADHD Pre-Kindergarteners · Intervention Types: Behavioral
Online Treatment
Behavioral
Experimental Group · 1 Intervention: Promoting Engagement with ADHD Pre-Kindergarteners · Intervention Types: Behavioral

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 5 years

Who is running the clinical trial?

Institute of Education Sciences (IES)UNKNOWN
1 Previous Clinical Trials
615 Total Patients Enrolled
Lehigh UniversityLead Sponsor
11 Previous Clinical Trials
3,453 Total Patients Enrolled
Lee Kern, Ph.D.Principal InvestigatorLehigh University
George J DuPaul, Ph.D.Principal InvestigatorLehigh University

Eligibility Criteria

Age < 18 · All Participants · 2 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
Children had to have met DSM-5 criteria for one of the three presentations of ADHD based on clinical interview and parent and teacher behavior ratings, including parent and teacher report of elevated levels of impairment at home and school (i.e.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 18th, 2021

Last Reviewed: October 25th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.